Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 20, 2003

View Archived Issues

Two series of GSK-3 kinase inhibitors discovered by Lilly researchers

Takeda claims JNK inhibitors for heart failure, arthritis and other uses

Ferring presents new plasma kallikrein inhibitors for use in inflammatory disorders

Novel 5-HT receptor ligands reported in recent patent

Optically active IKK-beta inhibitor covered by Bayer patent

Novel antimalarial artemisin derivatives reported in Bayer patent

Tigecycline as an alternative to vancomycin in MRSA osteomyelitis

Chemokine inhibition as potential novel therapy for endometriosis, postsurgical adhesions

ACP-2127 advanced into preclinical testing

Archemix selects ARC-183 for development

AstraZeneca and Abgenix enter cancer antibody alliance

FDA accepts for filing NDA for ultra-low-dose transdermal estrogen patch

Cardiome and Fujisawa enter RSD-1235 partnership

IDM to coordinate Europe project for optimization of prostate cancer vaccine

Medicure seeks clearance to begin phase II study of MC-1 in CABG patients

Oxytrex phase II study meets endpoints

Visudyne approved in Japan for wet AMD

Titan acquires congestive heart failure drug DITPA

SBIR grant funds development of niprisan for sickle cell disease

Community-based trial compares Concerta and Strattera for ADHD

Liraglutide has beneficial effects on food intake and body weight in obese minipigs

Vasopressin V2 receptor antagonist effective in early and established polycystic kidney disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...